Monoclonal antibody 17F9

Drug Profile

Monoclonal antibody 17F9

Latest Information Update: 20 Jul 2007

Price : $50

At a glance

  • Originator Cetus; Stanford University School of Medicine
  • Developer Stanford University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Leukaemia

Most Recent Events

  • 20 Jul 2000 Discontinued for Leukaemia in USA (unspecified route)
  • 18 Jan 1995 No-Development-Reported for Leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top